- Previous Close
3.9200 - Open
3.8600 - Bid 3.7400 x 80000
- Ask 3.8000 x 80000
- Day's Range
3.8600 - 3.8600 - 52 Week Range
3.4000 - 4.1200 - Volume
500 - Avg. Volume
7 - Market Cap (intraday)
386.185M - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
128.67 - EPS (TTM)
0.0300 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Knight Therapeutics Inc. operates as a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceutical products in Canada and Latin America. The company was founded in 2014 and is based in Montreal, Canada. It operates in additional locations in Latin America, such as Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, and Uruguay.
www.knighttx.com745
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 04K.F
View MorePerformance Overview: 04K.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 04K.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 04K.F
View MoreValuation Measures
Market Cap
376.95M
Enterprise Value
297.62M
Trailing P/E
150.09
Forward P/E
133.33
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.64
Price/Book (mrq)
0.76
Enterprise Value/Revenue
1.25
Enterprise Value/EBITDA
7.19
Financial Highlights
Profitability and Income Statement
Profit Margin
1.17%
Return on Assets (ttm)
0.48%
Return on Equity (ttm)
0.56%
Revenue (ttm)
371.3M
Net Income Avi to Common (ttm)
4.33M
Diluted EPS (ttm)
0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
172.84M
Total Debt/Equity (mrq)
6.22%
Levered Free Cash Flow (ttm)
-9.7M